Participation in “Cells in Motion”

  • Project FF-2014-03: In vivo intratumoral accumulation of cytotoxic drugs by tumor vascular infarction with retargeted tissue factor tTF-NGR (Wolfgang Berdel, Carsten Höltke, Stefan Wagner, Bernhard Wünsch, project time: 04/2014 - 03/2015)
  • Papers in the research focus “cell dynamics and imaging”

    2019

    Gerwing M, Herrmann K, Helfen A, Schliemann C, Berdel WE, Eisenblatter M, Wildgruber M. The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches. Nat Rev Clin Oncol 2019;16: 442-458. Abstract
    Hoeink A, Persigehl T, Kwiecien R, Balthasar M, Mesters R, Berdel W, Heindel W, Bremer C, Schwoppe C. Gadofosveset-enhanced MRI as simple surrogate parameter for real-time evaluation of the initial tumour vessel infarction by retargeted tissue factor tTF-NGR. Oncol Lett 2019;17: 270-280. Abstract

    2018

    Angenendt L, Mikesch J-H, Gorlich D, Busch A, Arnhold I, Rudack C, Hartmann W, Wardelmann E, Berdel WE, Stenner M, Schliemann C, Grunewald I. Stromal collagen type VI associates with features of malignancy and predicts poor prognosis in salivary gland cancer. Cell Oncol (Dordr) 2018;41: 517-525. Abstract
    Bäumer N, Rehkamper J, Appel N, Terheyden L, Hartmann W, Wardelmann E, Buchholz F, Muller-Tidow C, Berdel WE, Baumer S. Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. PLoS One 2018;13: e0200163. Abstract
    Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harrach S, Stalmann U, Schmidt LH, Gosheger G, Hardes J, Andreou D, Dreischaluck J, Lenz G, Wardelmann E, Mesters RM, Schwoppe C, Berdel WE, Hartmann W, Schliemann C. Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma. Transl Oncol 2018;11: 1271-1282. Abstract
    Mikesch J-H, Hartmann W, Angenendt L, Huber O, Schliemann C, Arteaga MF, Wardelmann E, Rudack C, Berdel WE, Stenner M, Grunewald I. AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report. Cell Oncol (Dordr) 2018;41: 455–462. Abstract
    Mikesch J-H, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Kohler G, Lenz G, Muller-Tidow C, Berdel WE, Arteaga M-F. Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer. Eur Respir J 2018;52: 1701637. Abstract
    Spukti EU, Schmidt LH, Schulze A, Schliemann C, Gorlich D, Wardelmann E, Hartmann W, Lenz G, Berdel WE, Kerkhoff A. (90) Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience. Eur J Haematol 2018;101: 514-521. Abstract

    2017

    Baumer N, Berdel WE, Baumer S. Immunoprotein-Mediated siRNA Delivery. Mol Pharm 2017;14: 1339-1351. Abstract
    Brabetz O, Alla V, Angenendt L, Schliemann C, Berdel WE, Arteaga M-F, Mikesch J-H. RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations. Mol Ther Nucleic Acids 2017;6: 243-248. Abstract
    Dai B, Grau M, Juilland M, Klener P, Horing E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Johrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood 2017;129: 333-346. Abstract
    Erdmann T, Klener P, Lynch JT, Grau M, Vockova P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood 2017;130: 310-322. Abstract
    Gollner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein H-U, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stolzel F, Herold S, Ehninger G, Kohler G, Pan K-T, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Muller LP, Thiede C, Muller-Tidow C. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med 2017;23: 69-78. Abstract
    Lutz M, Schulze AB, Rebber E, Wiebe S, Zoubi T, Grauer OM, Kessler T, Kerkhoff A, Lenz G, Berdel WE. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. Cancer Res Treat 2017;49: 548-552. Abstract
    Meissner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Muller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M. Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events. Cold Spring Harb Mol Case Stud 2017;3Abstract
    Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Gorlich D, Marra A, Hillejan L, Muller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwoppe C, Hartmann W. Potential therapeutic impact of CD13 expression in non-small cell lung cancer. PLoS One 2017;12: e0177146. Abstract
    Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwöppe C, Hartmann W. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer. Lung Cancer 2017;113: 121-127. Abstract
    Schneider C, Oellerich T, Baldauf H-M, Schwarz S-M, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann M-L, Yakunin AF, Geisslinger G, Strobel P, Ferreiros N, Serve H, Keppler OT, Cinatl JJ. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med 2017;23: 250-255. Abstract
    Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Kohn M, Misiak D, Baumer N, Cui C, Gollner S, Oellerich T, Serve H, Garcia-Cuellar M-P, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein H-U, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hebert J, Sauvageau G, Pabst C, Huttelmaier S, Muller-Tidow C. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. Nat Cell Biol 2017;19: 844-855. Abstract

    2016

    Baumer N, Appel N, Terheyden L, Buchholz F, Rossig C, Muller-Tidow C, Berdel WE, Baumer S. Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown. Nat Protoc 2016;11: 22-36. Abstract
    Brand C, Schliemann C, Ring J, Kessler T, Baumer S, Angenendt L, Mantke V, Ross R, Hintelmann H, Spieker T, Wardelmann E, Mesters RM, Berdel WE, Schwoppe C. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor. Oncotarget 2016;7: 6774-6789. Abstract
    Pohlen M, Groth C, Sauer T, Gorlich D, Mesters R, Schliemann C, Lenz G, Muller-Tidow C, Buchner T, Berdel WE, Stelljes M. Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (60 years). Bone Marrow Transplant 2016;51: 1441-1448. Abstract
    Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch J-H, Schliemann C, Lenz G, Muller-Tidow C, Buchner T, Krug U, Stelljes M, Karch H, Peters G, Gerth HU, Gorlich D, Berdel WE. Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center. Haematologica 2016;101: 1208-1215. Abstract
    Schmidt LH, Kuemmel A, Schliemann C, Schulze A, Humberg J, Mohr M, Gorlich D, Hartmann W, Brockling S, Marra A, Hillejan L, Goletz S, Karsten U, Berdel WE, Spieker T, Wiewrodt R. Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC. Lung Cancer 2016;92: 8-14. Abstract
    Schmidt LH, Vietmeier B, Kaleschke G, Schulke C, Gorlich D, Schliemann C, Kessler T, Schulze AB, Buerke B, Kuemmel A, Thrull M, Wiewrodt R, Baumgartner H, Berdel WE, Mohr M. Thoracic Malignancies and Pulmonary Nodules in Patients under Evaluation for Transcatheter Aortic Valve Implantation (TAVI): Incidence, Follow Up and Possible Impact on Treatment Decision. PLoS One 2016;11: e0155398. Abstract
    Schulze I, Rohde C, Scheller-Wendorff M, Baumer N, Krause A, Herbst F, Riemke P, Hebestreit K, Tschanter P, Lin Q, Linhart H, Godley LA, Glimm H, Dugas M, Wagner W, Berdel WE, Rosenbauer F, Muller-Tidow C. Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. Blood 2016;127: 1575-1586. Abstract
    Stucke-Ring J, Ronnacker J, Brand C, Holtke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wunsch B, Muller-Tidow C, Mesters RM, Schwoppe C, Berdel WE. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. Oncotarget 2016;7: 82458-82472. Abstract
    Uttarkar S, Piontek T, Dukare S, Schomburg C, Schlenke P, Berdel WE, Muller-Tidow C, Schmidt TJ, Klempnauer K-H. Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells. Mol Cancer Ther 2016;15: 2905-2915. Abstract
    Vogt N, Dai B, Erdmann T, Berdel WE, Lenz G. The molecular pathogenesis of mantle cell lymphoma. Leuk Lymphoma 2016: 1-8. Abstract

    2015

    Agelopoulos K, Richter GHS, Schmidt E, Dirksen U, von Heyking K, Moser B, Klein H-U, Kontny U, Dugas M, Poos K, Korsching E, Buch T, Weckesser M, Schulze I, Besoke R, Witten A, Stoll M, Kohler G, Hartmann W, Wardelmann E, Rossig C, Baumhoer D, Jurgens H, Burdach S, Berdel WE, Muller-Tidow C. Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. Clin Cancer Res 2015;21: 4935-4946. Abstract
    Baumer S, Baumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, Wardelmann E, Buchholz F, Berdel WE, Muller-Tidow C. Antibody-Mediated Delivery of Anti-KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer. Clin Cancer Res 2015;21: 1383-1394. Abstract
    Borschel N, Schwoppe C, Zerbst C, Angenendt L, Kessler T, Klapper W, Giovannoni L, Elia G, Neri D, Berdel WE, Mesters RM, Schliemann C. Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature. Leuk Res 2015;39: 739-748. Abstract
    Brand C, Dencks S, Schmitz G, Muhlmeister M, Stypmann J, Ross R, Hintelmann H, Schliemann C, Muller-Tidow C, Mesters RM, Berdel WE, Schwoppe C. Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor. J Ultrasound Med 2015;34: 1227-1236. Abstract
    Brand C, Frohlich M, Ring J, Schliemann C, Kessler T, Mantke V, Konig S, Lucke M, Mesters RM, Berdel WE, Schwoppe C. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR. Mol Pharm 2015;12: 3749-3758. Abstract
    Bulk E, Ay A-S, Hammadi M, Ouadid-Ahidouch H, Schelhaas S, Hascher A, Rohde C, Thoennissen NH, Wiewrodt R, Schmidt E, Marra A, Hillejan L, Jacobs AH, Klein H-U, Dugas M, Berdel WE, Muller-Tidow C, Schwab A. Epigenetic dysregulation of KCa 31 channels induces poor prognosis in lung cancer. Int J Cancer 2015;137: 1306-1317. Abstract
    Hillgruber C, Poppelmann B, Weishaupt C, Steingraber AK, Wessel F, Berdel WE, Gessner JE, Ho-Tin-Noe B, Vestweber D, Goerge T. Blocking neutrophil diapedesis prevents hemorrhage during thrombocytopenia. J Exp Med 2015;212: 1255-1266. Abstract
    Oelmann E, Stein H, Berdel WE, Herbst H. Expression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma. PLoS One 2015;10: e0138747. Abstract
    Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N, Singh J, Padgett RA, Gu X, Phillips JG, Clemente M, Parker Y, Lindner D, Dienes B, Jankowsky E, Saunthararajah Y, Du Y, Oakley K, Nguyen N, Mukherjee S, Pabst C, Godley LA, Churpek JE, Pollyea DA, Krug U, Berdel WE, Klein H-U, Dugas M, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Yoshida K, Ogawa S, Muller-Tidow C, Maciejewski JP. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell 2015;27: 658-670. Abstract
    Schliemann C, Gutbrodt KL, Kerkhoff A, Pohlen M, Wiebe S, Silling G, Angenendt L, Kessler T, Mesters RM, Giovannoni L, Schafers M, Altvater B, Rossig C, Grunewald I, Wardelmann E, Kohler G, Neri D, Stelljes M, Berdel WE. Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Cancer Immunol Res 2015;3: 547-556. Abstract
    Schmidt LH, Kummel A, Gorlich D, Mohr M, Brockling S, Mikesch JH, Grunewald I, Marra A, Schultheis AM, Wardelmann E, Muller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS One 2015;10: e0136023. Abstract
    Wenge DV, Felipe-Fumero E, Angenendt L, Schliemann C, Schmidt E, Schmidt LH, Thiede C, Ehninger G, Berdel WE, Arteaga M-F, Mikesch J-H. MN1-Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells. Oncogenesis 2015;4: e179. Abstract

    2014

    Baumer N, Baumer S, Berkenfeld F, Stehling M, Kohler G, Berdel WE, Muller-Tidow C, Tschanter P. Maintenance of leukemia-initiating cells is regulated by the CDK inhibitor Inca1. PLoS One 2014;9: e115578. Abstract
    Baumer N, Krause A, Kohler G, Lettermann S, Evers G, Hascher A, Baumer S, Berdel WE, Muller-Tidow C, Tickenbrock L. Proteinase-Activated Receptor 1 (PAR1) regulates leukemic stem cell functions. PLoS One 2014;9: e94993. Abstract
    Bettenworth D, Nowacki TM, Ross M, Kyme P, Schwammbach D, Kerstiens L, Thoennissen GB, Bokemeyer C, Hengst K, Berdel WE, Heidemann J, Thoennissen NH. Nicotinamide treatment ameliorates the course of experimental colitis mediated by enhanced neutrophil-specific antibacterial clearance. Mol Nutr Food Res 2014;58: 1474-1490. Abstract
    Hascher A, Haase A-K, Hebestreit K, Rohde C, Klein H-U, Rius M, Jungen D, Witten A, Stoll M, Schulze I, Ogawa S, Wiewrodt R, Tickenbrock L, Berdel WE, Dugas M, Thoennissen NH, Muller-Tidow C. DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes. Clin Cancer Res 2014;20: 814-826. Abstract
    Liersch R, Muller-Tidow C, Berdel WE, Krug U. Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. Br J Haematol 2014;165: 17-38. Abstract
    Persigehl T, Ring J, Bremer C, Heindel W, Holtmeier R, Stypmann J, Claesener M, Hermann S, Schafers M, Zerbst C, Schliemann C, Mesters RM, Berdel WE, Schwoppe C. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging. Angiogenesis 2014;17: 235-246. Abstract
    Schoofs T, Berdel WE, Muller-Tidow C. Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia 2014;28: 1-14. Abstract

    2013

    Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W, Berdel WE, Neri D. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 2013;5: 201ra118. Abstract
    Schoofs T, Rohde C, Hebestreit K, Klein H-U, Gollner S, Schulze I, Lerdrup M, Dietrich N, Agrawal-Singh S, Witten A, Stoll M, Lengfelder E, Hofmann W-K, Schlenke P, Buchner T, Hansen K, Berdel WE, Rosenbauer F, Dugas M, Muller-Tidow C. DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding. Blood 2013;121: 178-187. Abstract
    Schwöppe C, Zerbst C, Fröhlich M, Schliemann C, Kessler T, Liersch R, Overkamp L, Holtmeier R, Stypmann J, Dreiling A, König S, Höltke C, Lücke M, Müller-Tidow C, Mesters RM, Berdel WE. Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor. J Med Chem 2013;56: 2337-2347. Abstract

    2012

    Bulk E, Yu J, Hascher A, Koschmieder S, Wiewrodt R, Krug U, Timmermann B, Marra A, Hillejan L, Wiebe K, Berdel WE, Schwab A, Muller-Tidow C. Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer. PLoS One 2012;7: e44591. Abstract